Changzheng Li

Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial

Xiangyu Gao, Nong Xu, Ziyu Li et al. · The Lancet Oncology · 2023 · 197 citations

Pharmacy, Oncology, Pharmacology +16

Sphingosine kinase 1 promotes liver fibrosis by preventing miR‐19b‐3p‐mediated inhibition of CCR2

Tian Lan, Changzheng Li, Guizhi Yang et al. · Hepatology · 2018 · 155 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17

Andrographolide ameliorates diabetic nephropathy by attenuating hyperglycemia-mediated renal oxidative stress and inflammation via Akt/NF-κB pathway

Xiaoqian Ji, Changzheng Li, Yitao Ou et al. · Molecular and Cellular Endocrinology · 2016 · 111 citations

Medicine, Nephrology, Pharmacology +16

Amino acid catabolism regulates hematopoietic stem cell proteostasis via a GCN2-eIF2α axis

Changzheng Li, Binghuo Wu, Yishan Li et al. · Cell stem cell · 2022 · 91 citations

Life Sciences, Biochemistry, Molecular Biology +13

First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial

Lin Shen, Yanqiao Zhang, Ziyu Li et al. · Nature Medicine · 2025 · 81 citations

Medicine, Oncology, Pharmacology +11